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Introduction: Blood lactate levels are increasingly used to monitor patients. Steroids are frequently administered to
critically ill patients. However, the effect of steroids on lactate levels has not been adequately investigated. We
studied the effect of a single intraoperative high dose of dexamethasone on lactate and glucose levels in patients
undergoing cardiac surgery.
Methods: The Dexamethasone for Cardiac Surgery (DECS) trial was a multicenter randomized trial on the effect of
dexamethasone 1 mg/kg versus placebo on clinical outcomes after cardiac surgery in adults. Here we report a
pre-planned secondary analysis of data from DECS trial participants included at the University Medical Center
Groningen. The use of a computer-assisted glucose regulation protocol—Glucose Regulation for Intensive care
Patients (GRIP)—was part of routine postoperative care. GRIP aimed at glucose levels of 4 to 8 mmol/L. Primary
outcome parameters were area under the lactate and glucose curves over the first 15 hours of ICU stay (AUC15).
ICU length of stay and mortality were observed as well.
Results: The primary outcome could be determined in 497 patients of the 500 included patients. During the first
15 hours of ICU stay, lactate and glucose levels were significantly higher in the dexamethasone group than in the
placebo group: lactate AUC15 25.8 (13.1) versus 19.9 (11.2) mmol/L × hour, P <0.001 and glucose AUC15 126.5 (13.0)
versus 114.4 (13.9) mmol/L × hour, P <0.001. In this period, patients in the dexamethasone group required twice as
much insulin compared with patients who had received placebo. Multivariate and cross-correlation analyses suggest
that the effect of dexamethasone on lactate levels is related to preceding increased glucose levels. Patients in the
placebo group were more likely to stay in the ICU for more than 24 hours (39.2%) compared with patients in the
dexamethasone group (25.0%, P = 0.001), and 30-day mortality rates were 1.6% and 2.4%, respectively (P = 0.759).
Conclusions: Intraoperative high-dose dexamethasone increased postoperative lactate and glucose levels in the
first 15 hours of ICU stay. Still, patients in the dexamethasone group had a shorter ICU length of stay and similar
mortality compared with controls.
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High doses of corticosteroids are often administered to
attenuate the inflammatory response to cardiac surgery
and cardiopulmonary bypass (CPB) [1]. Administration
of a corticosteroid such as methylprednisolone or dexa-
methasone during cardiac surgery is associated with a
reduced duration of postoperative mechanical ventilation
and intensive care unit (ICU) and hospital stay, probably
because of a lower risk of postoperative pulmonary
complications [1-4]. Still, controversy regarding their use
remains because of potential important adverse effects.
Corticosteroids increase insulin resistance and may in-
crease hyperglycemia and blood glucose variability. The
pronounced inflammatory response following cardiac
surgery and CPB contributes to decreased insulin secre-
tion and increased insulin resistance. Although too rigid
a regulation of blood glucose may increase the risk of
hypoglycemia, inadequate glucose control is associated
with increased ICU morbidity and mortality [5,6].
Studies on the influence of corticosteroids on lactate
levels are scarce, and their results are contradictory
[7,8]. Dexamethasone effectively reduces the production
of pro-inflammatory cytokines during cardiac surgery
and thus may reduce lactate production [7,9] on the one
hand, but increases the amount of substrate for lactate
formation (pyruvate from glucose) by increasing hepatic
glucose release and insulin resistance on the other.
Furthermore, dexamethasone increases catecholamine
production in the adrenal medulla via its stimulating effect
on phenylethanolamine-M-methyltransferase [10]. Cate-
cholamines affect splanchnic perfusion as well as muscle
Na-K-ATP-ase activity, Both of which may also lead to
increased lactate production [11,12].
Because blood glucose [5,13,14] and lactate levels
[15-20] are both well-established and important clinical
outcome predictors in ICU patients, including those after
cardiac surgery, we investigated the effect of a single intra-
operative high dose of dexamethasone on glucose control
and lactate levels after cardiac surgery. We studied a sub-
set of patients included in the Dexamethasone for Cardiac
Surgery (DECS) trial, a multicenter randomized trial re-
cently carried out in The Netherlands [3]. This trial found
a reduced risk of respiratory failure and infections and
reduced ICU and hospital length of stay in patients who
received dexamethasone. We assessed the effect of
dexamethasone on postoperative lactate and glucose
levels.
Methods
Study design and participants
The DECS trial is a multicenter randomized clinical trial
in which 4,494 cardiac surgery patients were randomly
assigned to receive either an intraoperative dose of 1 mg/kg
dexamethasone or placebo. A detailed description of thedesign and results of the DECS trial was recently pub-
lished [3]. The institutional review board (Medical Ethics
Committee, in Dutch: Medisch Ethische Toetsingscom-
missie, METc) of the University Medical Center Utrecht
as well as the institutional review board (METc) of the
University Medical Center Groningen approved the DECS
trial protocol, which adhered to Good Clinical Practice
guidelines and relevant national regulations and is regis-
tered in the National Institutes of Health Trial Registry
(ClinicalTrials.gov identifier: NCT00293592). All partici-
pants gave written informed consent.
Intervention, randomization, and blinding
According to a computer-generated 1:1 randomization
scheme, patients received a single intravenous (IV) bolus of
dexamethasone (20 mg/mL, 1 mg/kg, maximum 100 mg)
or placebo (NaCl 0.9%) immediately after induction of
general anesthesia. The trial pharmacy prepared the trial
medication in blocks of 40 numbered, indistinguishable
vials. Patients, investigators, and all of the patients’ care-
givers were blinded to treatment allocation. Surgery,
anesthesia, and CPB were conducted without modification
for the trial.
Patient recruitment
The DECS trial recruited adult patients who required
elective or urgent cardiac surgery with use of CPB, and
excluded off-pump and emergency surgeries and pa-
tients with a life expectancy of less than 6 months. For
the present study, data of all 500 DECS trial participants
who underwent surgery at the University Medical Center
Groningen, The Netherlands, were used, because this
center routinely uses a validated computer-assisted glu-
cose regulation protocol in the ICU.
Conduct of anesthesia
Pre-operative cardiac medication was continued until
the morning of surgery. Patients were fasted from solid
foods for 6 hours and from clear fluids for 2 hours prior
to surgery. Patients did not receive supplemental enteral
or parental feeding during the pre-operative fasting
period. Standard anesthetic management consisted of
propofol, sufentanil, and a non-depolarizing muscle relax-
ant. Etomidate was only incidentally used as an induction
agent. Intraoperatively, glucose-free IV maintenance fluids
were used in all patients. CPB was performed by using
non-pulsatile flow of 2.4 L/min per m2, mild hypothermia
(32°C to 34°C), and a combined glucose-free colloid/crys-
talloid priming solution. Myocardial protection consisted
of cold blood cardioplegia or cold glucose-free crystalloid
solution (Plegisol; Abbott Laboratories, North Chicago,
IL, USA). Postoperatively, sedation was continued with
propofol and morphine. During the first 24 hours of ICU
stay, the standard feeding protocol consisted of 25 g of
Ottens et al. Critical Care  (2015) 19:41 Page 3 of 13intravenous glucose (1,000 mL glucose/saline solution)
and no additional enteral feeding.
Lactate and glucose monitoring and insulin therapy
In the ICU, a computer-assisted glucose control protocol
named Glucose Regulation for Intensive care Patients
(GRIP) was used [21]. GRIP recommends an insulin infu-
sion rate and glucose sampling frequency. The algorithm,
which is described in more detail elsewhere [21] and was
validated in 2,800 patients [22], is based on both the
current glucose level (queried automatically from the hos-
pital information system) and the change in recent glucose
values. GRIP-assisted glucose control, targeting for a glu-
cose level between 4 and 8 mmol/L, was applied as part of
routine care during the postoperative ICU stay of all
patients in this study. According to the protocol, short-
acting insulin (NovoRapid, Novo Nordisk, Alphen a/d
Rijn, The Netherlands) was administered intravenously via
a syringe pump. Intraoperatively, anesthesiologists used a
glucose regulation protocol targeting for a blood glucose
level below 10 mmol/L but did not use GRIP. Glucose
and lactate levels were obtained as part of routine intraop-
erative blood gas analysis. All blood samples were ana-
lyzed on point-of-care ABL Blood Gas Analyzer machines
(Radiometer, Copenhagen, Denmark). The analyzers were
subject to strict laboratory quality control.
Outcome measures
The primary outcome was the area under the curve
(AUC) of glucose and lactate levels in the first 15 hours
of postoperative ICU stay. The AUC was calculated by
using the trapezoid rule approximation method, with no
threshold for normal values. After 15 hours, most pa-
tients were discharged to the surgical ward, where GRIP
was not used, glucose levels were measured less fre-
quently, and lactate levels were measured rarely. When
patients arrived at the ICU, glucose and lactate levelsTable 1 Postoperative glucose control, insulin requirement, a
Outcome measurea Dex
Glucose AUC15 in mmol/L × hour 132.
Glucose level in mmol/L at postoperative ICU admission 10.0
Hyperglycemic index in mmol/Lb (cutoff >6.0 mmol/L) 2.70
Hyperglycemic index in mmol/Lc (cutoff >8.0 mmol/L) 1.14
Hypoglycemia incidence, N (%)d 0 (0
Lactate AUC15 in mmol/L × hour 25.9
Lactate level in mmol/L at postoperative ICU admission 2.1 (
Insulin consumption in IU at first 15 hours of ICU admission 46.6
To convert glucose to mg/dL, multiply by 18.02. To convert lactate to mg/dL, multip
as mean (standard deviation) unless otherwise indicated. bCalculated by dividing th
postoperative intensive care unit stay) that lies above 6.0 mmol/L by observation ti
8.0 mmol/L by observation time. dDefined as any glucose level of less than 4.0 mmwere always sampled. After that, the GRIP system deter-
mined the sampling frequency of glucose and lactate
levels, so the sampling frequency differs among patients.
This information is presented in Figure S1 (Additional
file 1). GRIP suggests a time interval to the next sample,
depending on previous glucose values and insulin infu-
sion rate. We therefore interpolated hourly glucose and
lactate values to calculate the AUC. Secondary outcomes
were total insulin consumption and the hyperglycemic
index (HGI) [23]. The HGI is a measure of overall
hyperglycemia that is not influenced by hypoglycemic
episodes or unequal sampling intervals. It is calculated
by dividing the area under the glucose curve that lies
above the upper limit of the normal range by the obser-
vation time. The HGI was calculated for two cutoff
values: 8.0 mmol/L as the upper end of our target glu-
cose range and 6.0 mmol/L according to the original
method of calculation described by Vogelzang et al. [23].
Intraoperatively, glucose and lactate were routinely sam-
pled at least three times: before, during, and after CPB.
Finally, we report ICU length of stay, ICU readmissions,
inotropic or vasopressor support requirement during the
ICU stay, postoperative surgical site infections, gastro-
intestinal hemorrhages, length of hospital stay, and
30-day mortality.
Regression model
Because the effect of dexamethasone on lactate levels
is not well understood, we evaluated the role of glu-
cose as an intermediate in the relation between
dexamethasone and postoperative lactate levels. In a
multivariate linear regression model, we assessed the
effect of dexamethasone on postoperative lactate levels
(AUC of the first 15 hours of postoperative ICU stay) and
added postoperative glucose levels (AUC of the first
15 hours of postoperative ICU stay) to the model as a
covariable.nd lactate level in a subgroup of patients with diabetes
amethasone (n = 62) Placebo (n = 58) P value
8 (16.2) 124.8 (16.5) 0.009
(2.5) 8.0 (2.3) <0.001
(1.00) 2.21 (1.00) 0.009
(0.91) 0.77 (0.76) 0.017
) 3 (5.2) 0.110
(9.7) 22.1 (16.2) 0.119
1.0) 1.7 (0.7) 0.007
(22.9) 28.3 (19.7) <0.001
ly by 9.01. aAll data refer to the first 15 postoperative hours and are presented
e part of the glucose AUC15 (area under the curve in the first 15 hours of
me. cCalculated by dividing the part of the glucose AUC15 that lies above
ol/L in the first 15 postoperative hours. ICU, intensive care unit.
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Two subgroup analyses were performed. We calculated
the main outcome measures separately for patients with
diabetes. The findings of this analysis are presented in
Table 1. A post hoc regression analysis on the effect of
beta-blocker use on the primary outcome was carried
out because of a significant baseline difference between
the groups.
Statistical analysis
The primary outcome was the AUC15 (first 15 postoper-
ative hours) of postoperative glucose and lactate levels.
To assess normality of distribution, frequency distribution247 Included in present analysis
 3 excluded from analysis
  1 Patient died shortly after surgery
  1 Withdrew informed consent 
  1 Unintentionally randomized without 
     informed consent
4220 Patients assesse
500 Randomiz
250 Randomized to dexamethasone group
     250 Received dexamethasone as randomized
1830 Eligible for 
Figure 1 Enrollment flowchart. The Dexamethasone for Cardiac Surgery
treated at eight participating hospitals in The Netherlands. This DECS trial s
University Medical Center Groningen.histograms with normality curves, as well as Levene’s test,
were used. We compared the AUC15 by using the Stu-
dent’s t test. If patients were discharged from the ICU
before the 15-hour observation period, the last glucose
and lactate value was carried forward to calculate the
AUC. To compare ICU length of stay between groups, the
log-rank test was used. To compare other continuous out-
comes, we used the Student’s t test or the Mann-Whitney
U test when appropriate. For dichotomous outcomes, we
calculated absolute risk difference and relative risk with
95% confidence interval and compared proportions by
using the χ2 test. We considered a two-tailed P value of
less than 0.05 to be statistically significant for the primary250 Included in present analysis
     0 Excluded from analysis
d for eligibility
1330 Excluded
 1255 Not invited or declined participation
     75 Provided informed consent, not randomized
  52 Surgery cancelled or rescheduled 
  23 Logistic reasons
ed
250 Randomized to placebo group
 250 Received placebo as randomized
2390 Not eligible for inclusion
 2077 Planned off-pump surgery
 313 Emergency surgery
inclusion
(DECS) trial was a multicenter study with 4,494 participants who were
ubstudy concerned patients who underwent cardiac surgery at the
Table 2 Demographic, clinical, and surgical characteristics of the dexamethasone and placebo groupsa
Characteristics Dexamethasone (n = 247) Placebo (n = 250) P value
Demographics
Male sex 158 (64) 159 (64) 0.83
Age in years, mean (SD) 66.8 (11.7) 66.5 (12.0) 0.78
Weight in kg, mean (SD) 82.1 (14.0) 82.3 (14.3) 0.91
Height in cm, mean (SD) 173 (9.3) 173 (9.2) 0.85
Comorbidities
Hypertension 146 (59) 151 (60) 0.73
Diabetes
Insulin-dependent 12 (5) 18 (7) 0.27
Non-insulin-dependent 50 (20) 40 (16) 0.23
Treatment for pulmonary disease 48 (19) 57 (23) 0.35
Previous cerebrovascular event
Stroke 7 (3) 12 (5) 0.55
Transient ischemic attack 12 (5) 14 (6) 0.70
Peripheral vascular disease 37 (15) 34 (14) 0.67
Pre-operative serum creatinine in mg/dL, mean (SD) 1.02 (0.44) 1.02 (0.42) 0.89
Cardiac status
Recent myocardial infarction (<90 days) 39 (16) 26 (10) 0.08
Left ventricular functionb
Moderate 82 (33) 93 (37) 0.33
Poor 15 (6) 14 (6) 0.83
EuroScore, median (IQR)c 6 (4-8) 6(4-8) 0.37
Pre-operative medication
Beta-blocker 171 (69) 151 (60) 0.05
Statin 142 (57) 125 (50) 0.13
Corticosteroid 21 (9) 17 (7) 0.83
Type of surgery 0.25
Isolated CABG 74 (30) 57 (23) 0.08
CABG plus valve 65 (26) 66 (26) 0.96
Single valve 95 (38) 104 (42) 0.45
Multiple valves 8 (3) 16 (6) 0.10
Other procedures 6 (2) 7 (3) 0.79
Repeat surgery 17 (7) 19 (8) 0.75
Duration of the procedure in minutes, mean (SD) 262 (91) 265 (86) 0.51
Duration of extracorporeal circulation in minutes, mean (SD) 147 (74) 149 (69) 0.70
Duration of aortic cross-clamping in minutes, mean (SD) 95 (49) 99 (46) 0.43
Type of anesthesia maintenance 0.92
Propofol 133 (53.6) 132 (52.8)
Volatile 115 (46.4) 118 (47.2)
Use of cell-saving device 17 (7) 23 (9) 0.34
Use of antifibrinolytic agent 179 (72) 179 (72) 0.72
International System conversion: To convert creatinine to μmol/L, multiply by 88.4. aData presented as number (percentage) unless otherwise indicated. bDefinition of
left ventricular function classes: moderate, ejection fraction of 30% to 50%; and poor, ejection fraction of less than 30% [24]. cHigher EuroScores indicate increased risk
of perioperative mortality [24]. CABG, coronary artery bypass grafting; IQR, interquartile range; SD, standard deviation.
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measures, we considered a two-tailed P value of less
than 0.001 to be statistically significant. IBM SPSS 22
(IBM Corporation, Armonk, NY, USA) was used for all
analyses.Results
Study population
Between February 2008 and July 2011, 500 patients
were enrolled and randomly assigned in the DECS
trial at the University Medical Center Groningen. One
patient withdrew informed consent during the first year
of follow-up. One patient was unintentionally randomly
assigned without having provided informed consent.
Both patients were excluded from the analysis. One pa-
tient died within 2 hours after ICU admission and was
excluded from the primary outcome analysis. Postopera-
tively, seven patients were not admitted to the cardio-
thoracic ICU but to other ICUs where lactate levels
were not routinely measured. For these patients, only
the AUC15 for glucose could be calculated. The en-
rollment flowchart of this study is shown in Figure 1.
Patients’ baseline demographic, clinical, and surgical
characteristics were similar between the study groups,
except for pre-operative beta-blocker use (dexametha-
sone group 69% versus placebo group 60%, P = 0.046)
(Table 2).Table 3 Postoperative outcomes in the dexamethasone and p
Outcome measurea
Glucose AUC15 in mmol/L × hour
Glucose level in mmol/L at postoperative ICU admission
Hyperglycemic index in mmol/Lb (cutoff >6.0 mmol/L)
Hyperglycemic index in mmol/Lc (cutoff >8.0 mmol/L)
Hypoglycemia incidence, N (%)d
Lactate AUC15 in mmol/L × hour
Lactate level in mmol/L at postoperative ICU admission
Insulin consumption in IU at first 15 hours of ICU admission
ICU length of stay in hours, median (IQR)
ICU length of stay ≥24 hours, N (%)
ICU readmissions, N (%)
Hospital length of stay in days, median (IQR)
Postoperative inotropic or vasopressor requirement, N (%)
Postoperative surgical site infections, N (%)
Postoperative gastrointestinal hemorrhage, N (%)
30-day mortality, N (%)e
To convert glucose to mg/dL, multiply by 18.02. To convert lactate to mg/dL, multip
as mean (standard deviation) unless otherwise indicated. bCalculated by dividing th
postoperative intensive care unit stay) that lies above 6.0 mmol/L by observation ti
8.0 mmol/L by observation time. dDefined as any glucose level of less than 4.0 mm
noradrenalin, dopamine, dobutamine, or milrinone during the first 24 hours of intenOutcomes
Table 3 shows the primary outcome of the study. The mean
areas under the glucose curve during the first 15 hours of
postoperative ICU admission were 126.5 mmol/L × hour in
the dexamethasone group and 114.4 mmol/L × hour in
the placebo group (P <0.001) (Figure 2; individual curves
in Figure S2, Additional file 1). In the first 15 hours of
postoperative ICU admission, patients who received dexa-
methasone required approximately twice as much insulin
compared with patients who received placebo (32.0 versus
16.3 units, P <0.001) (Figure 3). More frequent insulin in-
fusion rate adjustments were necessary to control glucose
levels in patients who received dexamethasone (Figure S1
and Figure S2, Additional file 1). The mean areas under
the lactate curve during the first 15 hours after postopera-
tive ICU admission were 25.8 mmol/L × hour in the dexa-
methasone group and 19.9 mmol/L × hour in the placebo
group (P <0.001) (Figure 4; individual curves in Figure S2,
Additional file 1). Patients in the dexamethasone group
had a significantly shorter ICU length of stay: dexametha-
sone median (interquartile range, or IQR) 21.9 (4.3) versus
placebo 22.7 (24.5) hours, P <0.001 (Figure 5). Although
the difference in median length of stay is less than 1 hour,
more patients in the placebo group were not ready for dis-
charge from the ICU at 24 hours postoperatively. The
numbers of patients who stayed in the ICU for 24 hours
or longer were 62 (25.0%) in the dexamethasone group
and 98 (39.2%) in the placebo group (P = 0.001). At 30-daylacebo groups
Dexamethasone Placebo P value
126.5 (13.0) 114.4 (13.9) <0.001
8.7 (2.3) 6.9 (2.0) <0.001
1.97 (0.85) 1.28 (0.81) <0.001
0.74 (0.69) 0.35 (0.51) <0.001
3 (1.2) 20 (8.0) <0.001
25.8 (13.1) 19.9 (11.2) <0.001
2.1 (1.0) 1.6 (0.7) <0.001
32.0 (19.9) 16.3 (14.5) <0.001
21.9 (19.3-23.7) 22.7 (20.6-45.0) 0.001
62 (25.0) 98 (39.2) 0.001
13 (5.2) 10 (4.0) 0.51
10 (8-16) 11 (8-16) 0.53
125 (50.6) 144 (57.6) 0.14
5 (2.0) 6 (2.4) 0.77
3 (1.2) 1 (0.4) 0.37
4 (1.6) 6 (2.4) 0.76
ly by 9.01. aAll data refer to the first 15 postoperative hours and are presented
e part of the glucose AUC15 (area under the curve in the first 15 hours of
me. cCalculated by dividing the part of the glucose AUC15 that lies above
ol/L in the first 15 postoperative hours. eDefined as any use of adrenalin,
sive care unit stay. ICU, intensive care unit; IQR, interquartile range.
5,5
6,5
7,5
8,5
9,5
10,5
11,5
12,5
Dexamethasone
Placebo
151413121110987654321ICU
admission
Post
CPB
CPBPre
CPB
Glucose mmol/L
Time *   *   *   *    *     *      *       *       *        *          *          *                         *  * *
100
120
140
160
180
180
200
220
Glucose mg/d L
Figure 2 Intraoperative and postoperative glucose levels. Mean (standard deviation) glucose levels are shown. The mean AUC15 (area under
the curve in the first 15 hours of postoperative intensive care unit stay) values were 127 mmol/L × hour for the dexamethasone group and
114 mmol/L × hour for the placebo group (P <0.001). To convert glucose to mg/dL, multiply by 18.02.
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(1.6%) and six patients in the placebo group (2.4%)
had died.
Regression analysis shows that the association between
treatment with dexamethasone and increase postopera-
tive lactate levels is no longer statistically significant
when postoperative glucose level is added as a covari-
able. This suggests that dexamethasone exerts its effect
on postoperative lactate levels mainly via glucose. Re-
gression betas and P values are presented in Table S1 in
Additional file 1.
Post hoc bivariate cross-correlation analysis shows that
glucose levels had the strongest correlation with lactate
levels 2 hours later. These data are presented in Table S2
in Additional file 1.
In the subgroup of patients with diabetes (n = 120), a
similar effect of dexamethasone on glucose AUC15
was observed, compared with patients without diabetes.
However, in patients with diabetes, the lactate AUC15 didnot differ (Table 1). Pre-operative beta-blocker use was in-
dependently associated with a small increase in postopera-
tive glucose levels (beta 3.720, P = 0.003) but not lactate
levels (beta 1.921, P = 0.096).
Discussion
This randomized trial of 497 cardiac surgery patients
showed that a single intraoperative high dose of dexa-
methasone leads to significantly increased lactate and
glucose levels in the early postoperative period, with the
use of a computer-assisted glucose control system. In
the early postoperative period, the average insulin re-
quirement was two times the average amount required
in patients who received placebo. Still, patients who re-
ceived dexamethasone were more likely to be discharged
from the ICU within 24 hours after surgery compared
with patients who received placebo, as previously observed
in the parent trial [3]. Bivariate correlation analysis and
multivariate regression analysis suggest that the higher
0,5
1,0
1,5
2,0
2,5
3,0
Dexamethasone
Placebo
151413121110987654321ICU
admission
Units of insulin / hour
Time
Figure 3 Postoperative insulin infusion rate, as prescribed by the Glucose Regulation for Intensive care Patients (GRIP) system. Median
(interquartile range) infusion rate in units of short-acting insulin/hour is shown. Mean cumulative insulin doses (first 15 hours of intensive care unit
stay) were 32.0 units in the dexamethasone group and 16.3 units in the placebo group (P <0.001).
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may largely be responsible for the higher lactate levels.
Lactate measurement and corticosteroid administration
are widely used, and both arguably have a unique position
in critical care. Lactate has emerged as one of the most use-
ful prognostic laboratory parameters to predict poor out-
come [15,18,19]. Recent studies have demonstrated that
lactate can be used to monitor the adequacy of circulatory
management and that treatment targeted towards reducing
lactate levels has clinical benefit in ICU patients [25]. On
the therapeutic side, corticosteroid therapy is probably the
most debated intervention in critical care [1,2,4,26]. Against
this background, it is surprising that relatively little evi-
dence exists on the direct impact of corticosteroids
upon lactate levels. Other than the aforementioned
small studies from 1997 and 2003, we are not aware of
other randomized double-blind placebo-controlledstudies that have studied the effect of high-dose cortico-
steroids on postoperative lactate levels [7,8].
Our observation has practical consequences regarding
the prognostic value of moderately increased lactate and
glucose levels. In this study, patients who received dexa-
methasone had higher lactate levels, required more insu-
lin, and had higher glucose levels, but the parent trial (n =
4,494) showed that dexamethasone reduced ICU length of
stay and that there was no effect of dexamethasone on
major adverse events (7.0% after dexamethasone versus
8.5% after placebo, P = 0.07) [3]. The present substudy was
underpowered to evaluate the effect of dexamethasone on
major adverse events but confirmed the shorter length of
stay in the ICU found in the dexamethasone group in the
parent trial.
The pleiotropic effects of dexamethasone and the pleio-
tropic causes of hyperlactatemia make it impossible to
0,0
0,2
0,4
0,6
0,8
1,0
1,2
1,4
1,6
1,8
2,0
2,2
2,4
2,6
2,8
3,0
Lactate mmol/L
151413121110987654321ICU
admission
Post
CPB
CPBPre
CPB Time
*  *   *    *    *    *     *     *      *      *       * 
3,2
2,5
5,0
7,5
10,0
12,5
15,0
17,5
20,0
22,5
25,0
27,5
Lactate mg/dL
0,0
Dexamethasone
Placebo
Figure 4 Intraoperative and postoperative lactate levels. Mean (standard deviation) lactate levels are shown. Mean lactate AUC15 values were
26 mmol/L × hour in the dexamethasone group and 20 mmol/L × hour in the placebo group (P <0.001). To convert lactate to mg/dL, multiply by
9.01. *Difference between groups statistically significant (P <0.001 after Bonferroni correction). AUC15, area under the curve in the first 15 hours of
postoperative intensive care unit stay; CPB, cardiopulmonary bypass; ICU, intensive care unit.
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several potential stimulatory and inhibitory pathways that
may have played a role in the induction of higher lactate
levels in patients who received dexamethasone and the
strong relation of this effect with high glucose levels. Dexa-
methasone may reduce lactate production by inhibiting the
synthesis of pro-inflammatory cytokines associated with
increased lactate production [7,9,12,27-29]. This effect may
have been outweighed by dexamethasone’s effects on the
adrenergic stress response, which increases blood lactate
directly through increased catecholamine production in the
adrenal medulla. Indirectly, dexamethasone increases
lactate production through its effect on insulin resistance
and hepatic production of glucose, which increases blood
glucose, which is a substrate for lactate production [10-12].
In this study, multivariate regression suggests that the effect
of dexamethasone on lactate production is dependent on
its hyperglycemic effect.
Whether the positive relation between lactate and
corticosteroids that we observed is restricted to cardiac
surgery patients who receive high-dose dexamethasone
or whether it is also present in, for example, sepsis pa-
tients who receive comparatively lower doses of hydro-
cortisone is not known. Detailed analysis of glucose and
lactate measurements in sepsis patients might address
this question. In a recent retrospective study on therelation of hyperlactatemia and hyperglycemia with out-
come in a cohort of nearly 8,000 ICU patients, it was ob-
served that hyperlactatemia and hyperglycemia each had
a strong relation with mortality but that the independent
relation of hyperglycemia with outcome virtually dis-
appeared when hyperlactatemia and hyperglycemia were
included together. The investigators suggest that this
observation indicates that stress is a common cause for
increases of both lactate and glucose [32]. In the case of
dexamethasone administration, measurements of adren-
ergic stress hormone and cytokine levels might further
elucidate the pathways by which dexamethasone or other
corticosteroids influence glucose and lactate levels. Bivari-
ate cross-correlation analysis (presented in Table S2,
Additional file 1) supports the suggestion of a causal rela-
tion as reflected by the time course of the mean glucose
and lactate curves, namely that the glucose peak induces a
lactate peak a few hours later. Future studies with con-
tinuous monitoring of circulating glucose and lactate as
well as a sampling of mediators such as epinephrine and
registration of exogenous catecholamines may further
clarify the apparent temporal and potential causal relation
between the (postoperative) glucose peak and subsequent
lactate peak.
Several limitations apply to our study. This study has a
relatively short follow-up time. Most patients leave the
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Figure 5 Length of postoperative intensive care unit stay in the
dexamethasone and placebo groups. Box-plot of postoperative
intensive care unit length of stay is shown. Whiskers represent the
last datum within 1.5 times the interquartile range. Median (interquartile
range) lengths of stay were 21.9 (4.3) hours in the dexamethasone
group and 22.7 (24.5) hours in the placebo group (P <0.001) (log-rank
test). Note the difference between the median and mean lengths of
stay (Table 3).
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frequent glucose and lactate sampling, although as the
temporal data show, the period of maximal insulin re-
sistance has clearly passed by then.
In this study population, the 30-day mortality was 2%,
somewhat higher than the overall 30-day mortality in
the DECS trial (1.5%). This can be explained by a difference
in case mix, reflected by the higher median Euroscore of
the patients operated at the University Medical Center
Groningen compared with the overall Euroscore in the
DECS trial: 6 (IQR 4 to 8) versus 5 (IQR 3 to 7).
This study was performed at an ICU with a validated
computer-assisted glucose regulation protocol. We ex-
pect that, on average, glucose levels in both groups
would have been higher if less intensive glucose control
had been applied. The GRIP system advised much larger
insulin doses to patients who received dexamethasone.
We therefore expect that a larger difference between the
glucose levels of patients who received dexamethasone
versus those who received placebo would have occurred
in an environment with less intensive glucose control.
Because of the double blinding, modified glucose regu-
lation algorithms for patients receiving steroids could
not be used. Our results show that specific glucose regu-
lation algorithms for cardiac surgery patients receiving
corticosteroids are important to prevent early postopera-
tive hyperglycemia.
The higher glucose levels in patients in the dexa-
methasone group may have indicated the treatment allo-
cation in some patients. Still, there was a considerable
overlap of postoperative glucose levels in the different
treatment groups (Figure S2, Additional file 1), and insu-
lin dose changes were prescribed by the GRIP computer
system and applied by nurses, who were not involved in
the analysis of the data.
A final important limitation of our study is the dif-
ference in the number of patients who used beta-
blockers at baseline, despite adequate randomization.
Pre-operative beta-blocker use was associated with a
small but statistically significant increase in postopera-
tive glucose levels but not lactate levels. More patients
randomly assigned toward receiving dexamethasone used
beta-blockers pre-operatively. This may have contributed
to a part of the observed effect of dexamethasone on post-
operative glucose levels.Conclusions
In this randomized clinical trial of 498 patients, the
administration of intraoperative high-dose dexame-
thasone was associated with significantly higher post-
operative lactate and glucose levels after cardiac
surgery but was associated with decreased ICU length
of stay.
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Figure 6 The influence of dexamethasone on glucose and lactate levels. (1) Dexamethasone reduces production of pro-inflammatory cyto-
kines. (2) In the adrenergic medulla, dexamethasone increases catecholamine production. (3) Dexamethasone stimulates hepatic glucose produc-
tion and increases insulin resistance. (4) Glucose can be metabolized to pyruvate and to lactate via lactate dehydrogenase. (5) Catecholamine
stimulation can increase lactate production via increased Na-K-pump activity [10-12,27-31].
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 Dexamethasone increases postoperative glucose
levels and insulin requirements in patients who
undergo cardiac surgery.
 Dexamethasone increases postoperative lactate levels
in patients who undergo cardiac surgery.
 Our data suggest that the increase in lactate levels
may be directly related to the increased glucose levels.
 Although high-dose dexamethasone therapy caused
an increase in glucose and lactate levels, the treatment
was not associated with increased mortality and was
associated with shorter intensive care unit length of stay.
 If dexamethasone is administered to cardiac surgery
patients, clinicians should anticipate higher insulin
requirements and be aware that small increases in
lactate levels in such patients are not necessarily
related to poor outcome.Additional file
Additional file 1: Figure S1. Lactate and glucose sampling frequency
and number of insulin infusion rate adjustments in the first 15 hours of
postoperative intensive care unit stay. The figure shows a graphical
representation of difference in sampling frequency of lactate and glucose
and insulin infusion rate adjustments between the dexamethasone and
placebo groups during the observation period of the study. Figure S2.
Individual measurements of glucose, lactate, and insulin infusion rate in
the dexamethasone and placebo groups. The figure shows a graphical
representation of unadjusted (individual) measurements of glucose and
lactate levels and the actual insulin infusion rate during the observation
period of the study. Table S1. Multivariate linear regression model of the
effect of dexamethasone on postoperative lactate levels. The table shows
the linear regression models of the effect of treatment allocation (to
dexamethasone or placebo) and postoperative glucose levels (area under
the curve in the first 15 hours of postoperative intensive care unit stay
(AUC15) on postoperative lactate levels (AUC15). Table S2. Bivariate
correlation matrix of glucose and lactate levels in the first 15 hours of
postoperative intensive care unit (ICU) stay. The table shows the bivariate
correlation coefficients of glucose and lactate levels at each time point in
the first 15 hours of postoperative ICU stay.
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AUC: area under the curve; AUC15: area under the curve in the first 15 hours
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